gustave roussy in paris is one of the world's leading cancer centres — often treating rare or complexof the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence and over—treating and the impact that that can have on a patient�*s health. and here, what's known as a non—interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long—term data is vital, the patients aren't told of the al's findings to avoid the risk of life—or—death treatment decisions being based on them. french and us tech company 0wkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer. this will provide some of the information needed to classify patients between having a high, intermediate or low risk of their disease returning within five years. we know that for this type of cancer, the prognosis is good, with more than 90% of patients being able to get rid of th

gustave roussy in paris is one of the world's leading cancer centres, often treating rare or complexnd therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence, and over—treating and the impact that that can have on a patient�*s health. and here, what's known as a non—interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long—term data is vital, the patients aren't told of the al's findings, to avoid the risk of life—or—death treatment decisions being based on them. french and us tech company 0wkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer. this will provide some of the information needed to classify patients between having a high, intermediate or low risk of their disease returning within five years. we know that for this type of cancer, the prognosis is good, with more than 90% of patients be able to get rid of the disease. in these patients

gustave roussy in paris is one of the world's leading cancer centres — often treating rare or complexment decisions being based on them. french and us tech company owkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer. this will provide some of the information needed to classify patients between having a high, intermediate or low risk of their disease returning within five years. we know that for this type of cancer, the prognosis is good, with more than 90% of patients being able to get rid of the disease. in these patients, we want to avoid as much as possible a heavy treatment that can be considered in itself as a new disease. so that's why you want to identify the patients that are not likely to relapse. owkin aims to complement everyday clinical practice with its tool. it can already be used in european hospitals and the company's working on an updated version for those in the uk. what does an oncologist who's used to having difficult conversations with patients make of it, though? what we do now in terms of assessment of the ri

gustave roussy in paris is one of the world's leading cancer centres, often treating rare or complexhen it comes to the balance between providing enough treatment to avoid recurrence and over—treating and the impact that that can have on a patient�*s health. and here, what's known as a non—interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long—term data is vital, the patients aren't told of the ai's findings to avoid the risk of life—or—death treatment decisions being based on them. french and us tech company 0wkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer. this will provide some of the information needed to classify patients between having a high, intermediate or low risk of their disease returning within five years. we know that, for this type of cancer, the prognosis is good, with more than 90% of patients be able to... to get rid of the disease. in these patients, we want to avoid as much as possible an over—treatment that can be considered in